

AREA PRESCRIBING COMMITTEE – ACTION LIST 15th DECEMBER 2016

Action Reference	Minute Reference	ACTION	OWNER	FURTHER COMMENTS	TARGET DATE	STATUS (R/A/Clear)
ACTIONS FOR 2016						
15/43	126/15	Azathioprine & Mercaptopurine SCG To be reviewed in light of gastroenterologist comments.	LA	LA awaiting reply from Dr Chris McDonald	09.02.2017	ONGOING
04/16	08/16	Transfer of care audit Actions from results still to complete: I. Report for Prescription Pad. II. Report to be uploaded to website.	LA LA		09.02.2017	ONGOING
21/16	46/16	TA388 Sacubitril valsartan Treating symptomatic chronic heart failure with reduced ejection fraction. Full NICE criteria to be added to first box. Include requirement for GPs to prescribe once secondary care reviewed and stable	NA	NA to feedback changes to author, final document to be circulated before the next meeting for comments.	09.02.2017	ONGOING
27/16	64/16	Psoriasis Biologics Agents consultation	LA	BLUETEQ forms to be updated for initiation and continuation	09.02.2017	ONGOING
31/16	68/16	Specials Guide –updated version (was Off-label uses of tablets and capsules)	LA	Comments to be returned to Phil Utting by the 20 th January 2017, final version to be brought to the next meeting.	09.02.2017	ONGOING
37/16	77/16	Formulary amendments: July 2016 Minor Ailments Formulary review	BM	BM to feedback to LPC.	09.02.2017	ONGOING

49/16	101/16	COPD Treatment Algorithm The algorithm was APPROVED for use with the following alterations: I. Re-name" COPD Inhaler decision tool" II. Important point 1. to read " Choose a device that the patient can use effectively" III. Can the abbreviation "CAT" have an explanation. IV. Trust Logos and approval / review dates to be added.	BG	Changes to be made and then document can be issued.	09.02.2017	ONGOING
57/16	117/16	Formulary amendments: October 2016 To be added to Prescription Pad	LA		09.02.2017	
58/16	118/16	TA418 Dapagliflozin - In triple therapy for treating type 2 diabetes, recommended as an option only in combination with metformin and a sulphonylurea. Noted - GREEN Cumbria Blood Glucose Algorithm to be updated	LA		09.02.2017	
59/16		TA419 Apremilast – Treating moderate to severe plaque psoriasis - Recommended–RED BLUETEQ form to be added	LA			
60/16	119/16	NG59: Low back pain and sciatica in over 16s: assessment and management. - Noted, NA to feedback to NCUHT at the D&T meeting.	NA LA	To be added to prescription Pad – not to refer patients for Spinal injections.	09.02.2017	

61/16	122/16	MEDICINES SAFETY Cumbria CCG has asked PRIMIS to create an audit for all patients prescribed Lithium, to include any interacting drugs. It will be possible for practices to run this monthly to ensure patients are monitored appropriately. Report to be brought to next meeting. CPFT to explore possibility of Cumbria wide database to include all patients prescribed lithium, to report to next meeting. Develop Shared Care Guidance	AL HH HH LA	To be added to prescription pad.	09.02.2017	
62/16	123/16	Guide to your Just in Case Medication – Updated version circulated, Trust logos, date and review dates to be added before circulation.	HH		09.02.2017	
63/16	125/16	RDTC reports – Q1 2016/17 <ul style="list-style-type: none"> Pain management – Above England average spend for non-opioid prescribing due to Nefopam. Hyaluronic acid prescribing – 2 practices to action. 	LA		09.02.2017	
64/16	126/16	Sodium Aurothiomalate (GOLD) SCG Review in line with BSR updated monitoring recommendations.	PB	Changes to be made and be brought to next meeting.	09.02.2017	
65/16	127/16	Methotrexate SCG To be updated to show all products and strengths available and brought back to next meeting.	LA		09.02.2017	
66/16	128/16	Diabetic foot infection guideline To be added to NECS MO website and add to Prescription Pad.	LA		09.02.2017	

67/16	129/16	Alirocumab and Evolocumab LDL cholesterol reduction BLUETEQ forms to be updated to include continue only if a 30% reduction has been achieved at 12 weeks.	LA		09.02.2017	
68/16	130/16	Hydroxycarbamide SCG Dermatology SCG is to be reviewed if it is still required, to be brought back to the next meeting.	PB		09.02.2017	
69/16	134/16	NTAG – Qutenza (capsaicin) cutaneous patch for neuropathic pain Cumbria usage to be brought to the next meeting.	LA	Noted – NOT RECOMMENDED for neuropathic pain	09.02.2017	
70/16	135/16	Cinacalcet RAG rating review Paper to be brought to the next meeting	NA		09.02.2017	
71/16	137/16	Denosumab prescribing guideline for primary care The following changes to be made to the document then circulated to the committee with comments back by the 20 th Jan 2017: <ul style="list-style-type: none"> I. Flow diagram to be added to the guideline. II. Remove red writing and the appendix. III. Remove paragraph 3 from the introduction section. 		Final version to be brought to the next meeting	09.02.2017	

72/16	138/16	Updated PPI Specials guideline The following change to be made: I. “patient” to be changed to “parent”	LA	To be added to NECS MO website and Prescription Pad.	09.02.2017	
73/16	140/16	Drug Safety Update (October 16)	LA	Add point 1 to Prescription Pad	09.02.2017	
74/16	141/16	Drug Safety Update (November 16)	LA	Add point 2 to Prescription Pad	09.02.2017	

	New action from current meeting
	Action over one meeting old
	Action over two meetings old